

Letters

Risk Stratification Using High-Sensitivity Cardiac Troponin T in Patients With Suspected Acute Coronary Syndrome



High-sensitivity cardiac troponin assays allow the early recognition of myocardial injury, and they have facilitated the development of early rule-out pathways to identify patients who do not have acute myocardial infarction. Although international guidelines recommend using the sex-specific 99th centile from a healthy reference population as the diagnostic threshold for myocardial infarction, it is increasingly evident that the use of lower thresholds to risk-stratify patients and rule-out myocardial infarction at presentation is safer and more effective.


We previously defined the optimal risk stratification threshold as the highest troponin concentration that gave a negative predictive value (NPV) for myocardial infarction or cardiac death at 30 days of 99.5%, to maximize effectiveness while maintaining safety (1). This goal was achieved by using a high-sensitivity cardiac troponin I assay at a concentration <5 ng/l, which identified two-thirds of patients as low risk at presentation and misclassified <1 in 200 patients. The performance of this risk stratification threshold has now been validated for both cardiac troponin I and T (2). We developed a simple early rule-out pathway, which incorporates separate risk stratification and diagnostic thresholds, and recognizes that small changes within the reference range may be important in those with intermediate troponin concentrations (3). In a prospective, stepped wedge, cluster randomized controlled trial, we recently showed that the introduction of this early rule-out pathway into clinical practice was both safe and effective (4). Whether this pathway performs equally well using the U.S. Food and Drug Administration-approved Roche Elecsys (Roche Diagnostics, Basel, Switzerland) high-sensitive cardiac troponin T assay is uncertain.

We recruited patients with suspected acute coronary syndrome from the emergency department of

the Royal Infirmary of Edinburgh, a tertiary care hospital in Scotland, between June 1, 2013, and March 31, 2017, into a substudy of the High-STEACS (High-Sensitivity Troponin in the Evaluation of Patients With Acute Coronary Syndrome) trial (3). We did not enroll patients with ST-segment elevation myocardial infarction, those unable to provide consent, or those from outside our region to ensure complete follow-up. Blood samples were obtained at presentation and at 3 and 6 to 12 h. Samples were centrifuged and stored at -80°C for batch processing. This clinical trial was registered (NCT01852123) and approved by the research ethics committee; patients provided written informed consent. The final diagnosis was adjudicated by 2 cardiologists, with consensus from a third where required.

We evaluated the performance of our rule-out pathway (Figure 1) applied by using the Roche Elecsys fifth-generation cardiac troponin T assay (limit of detection: 5 ng/l; 99th centile: 14 ng/l). In recognition of the U.S. Food and Drug Administration requirement not to report at a concentration of 5 ng/l, we performed a sensitivity analysis using a concentration of 6 ng/l at presentation. The primary outcome was type 1 myocardial infarction or cardiac death within 30 days.

We enrolled 1,951 patients with suspected acute coronary syndrome, of whom 1,859 had a cardiac troponin T result available at presentation. Myocardial injury was detected in 27.4% (509 of 1,859) of patients, with an adjudicated diagnosis of type 1 or type 2 myocardial infarction in 254 (13.7%) and 66 patients (3.6%), acute or chronic myocardial injury in 187 patients (10.1%), and 6 deaths from a cardiac cause at 30 days. The pathway identified 58.7% (1,092 of 1,859) of patients as low risk, with 6 missed events (5 index and 1 type 1 myocardial infarction at 30 days), for an NPV of 99.4% (95% confidence interval [CI]: 98.9% to 99.8%) and sensitivity of 97.5% (95% CI: 95.6% to 99.2%). This outcome compared favorably to the European Society of Cardiology 3-h pathway (5), which identified 64.2% (1,193 of 1,859) of patients as low risk, with 47 missed events (NPV: 96.0% [95% CI: 94.8% to 97.1%]; sensitivity: 81.7% [95% CI: 76.9% to 86.3%]). In the modified pathway using 6 ng/l at presentation, a similar performance was observed, with 59.2% (1,101 of 1,859) of patients

FIGURE 1 Performance of the High-STEACS Early Rule-Out Pathway for Cardiac Troponin T

identified as low risk, for an NPV of 99.3% (95% CI: 98.8% to 99.7%) and sensitivity of 97.1% (95% CI: 95.0% to 99.0%).

The High-STEACS early rule-out pathway seems both safe and effective when using a high-sensitivity cardiac troponin T assay, and it provides clinicians with a simple approach to triage patients with suspected acute coronary syndrome. Although our data are observational, they are consistent with the findings of our randomized controlled trial, and the pathway seems safer than guideline-recommended approaches using the 99th centile.

*Andrew R. Chapman, MD, PhD
Dennis Sandeman, MSc
Amy V. Ferry, PhD
Stacey Stewart, MN
Fiona E. Strachan, PhD
Ryan Wereski, MD
Anda Bularga, MD
Atul Anand, MD, PhD

Anoop S.V. Shah, MD, PhD
Nicholas L. Mills, MD, PhD

*BHF/University Centre for Cardiovascular Science
Chancellor's Building
University of Edinburgh
Edinburgh EH16 4SB, United Kingdom
E-mail: a.r.chapman@ed.ac.uk
Twitter: @chapdoc1

<https://doi.org/10.1016/j.jacc.2019.12.036>

© 2020 Published by Elsevier on behalf of the American College of Cardiology Foundation.

Please note: The High-STEACS trial was funded by the British Heart Foundation (SP/12/10/29922 and PG/15/51/31596). Drs. Mills is supported by the Butler Senior Clinical Research Fellowship (FS/16/14/32023) from the British Heart Foundation. Dr. Chapman is supported by a Clinical Research Training Fellowship (FS/16/75/32533) from the British Heart Foundation; and receives support from a Starter Grant for Clinical Lecturers by the Academy of Medical Sciences (SGL021/1075). Dr. Bularga is supported by a Scholarship (SS/CH/09/002/26360) from the British Heart Foundation. Dr. Wereski is supported by a Research Excellence Award (RE/18/5/34216) from the British Heart Foundation. Dr. Chapman, Mr. Sandeman, and Dr. Shah have received honoraria from Abbott Diagnostics. Dr. Mills has received honoraria or consultancy from Abbott Diagnostics, Roche Diagnostics, Siemens Healthineers, and LumiraDx; and has received research grants to the University of Edinburgh from Abbott and Siemens. All other authors have reported that they have no relationships relevant to the contents of

this paper to disclose. The authors thank the researchers from the Emergency Medicine Research Group Edinburgh for their support during the conduct of this trial.

REFERENCES

1. Chapman AR, Lee KK, McAllister DA, et al. Association of high-sensitivity cardiac troponin I concentration with cardiac outcomes in patients with suspected acute coronary syndrome. *JAMA* 2017;318:1913-24.
2. Pickering JW, Than MP, Cullen L, et al. Rapid rule-out of acute myocardial infarction with a single high-sensitivity cardiac troponin T measurement below the limit of detection. *Ann Intern Med* 2017;166:715-4.
3. Chapman AR, Anand A, Ferry A, et al. Comparison of the efficacy and safety of novel rule out pathways for acute myocardial infarction. *Circulation* 2017;135:1586-96.
4. High-sensitivity troponin at presentation to rule out myocardial infarction (HISTORIC). NCT03005158. Available at: <http://clinicaltrials.gov>. Accessed October 1, 2019.
5. Roffi M, Patrono C, Collet JP, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J* 2016;37:267-315.

Anticoagulant Therapy and Hip Fracture Risk



A Possible Involvement of Physical Activity

In their timely and important observational study using the Danish national registries that included 37,350 older adult patients with atrial fibrillation who received vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) over 180 days, Binding et al. (1) found that the use of DOACs was significantly associated with a decreased risk of any fracture but not hip fracture compared with the use of VKAs. Of note, the latter negative finding is compatible with the results of a recent meta-analysis indicating that there were no differences in the risk of hip or femoral neck fracture between the use of DOACs versus warfarin, a VKA, as previously pointed out (2); apart from DOACs, a number of observational studies have consistently shown that warfarin is not linked to hip fracture risk (3). Considering that hip fracture is the most severe osteoporotic fracture with substantial morbidity and mortality, I would like to discuss the possible mechanism involved.

Accumulating experimental and clinical evidence suggests that VKAs can impair bone material stiffness, but the impaired skeletal quality can be potentially compensated by functional adaptation to the mechanical environment, especially in highly weight-bearing regions such as the hip, which is supported by the higher bone mass in mice lacking osteocalcin or γ -glutamyl carboxylase (3,4). The compensation

theory means that hip fracture risk might be increased if mechanical loading during physical activity is insufficient. Consequently, although I agree with Gage (5) that the choice of DOACs or VKAs in elderly patients with atrial fibrillation is generally based on the risks of ischemic stroke and hemorrhage, monitoring, and cost rather than the risk of osteoporotic fractures (5), hip fracture risk could become a more considerable factor in the case of physical inactivity, which is 1 of the strong risk factors for osteoporotic fractures referred by the authors (1).

*Toshihiro Sugiyama, MD, PhD

*Department of Orthopaedic Surgery

Saitama Medical University

38 Morohongo, Moroyama

Saitama 350-0495

Japan

E-mail: tsugiyam@saitama-med.ac.jp

<https://doi.org/10.1016/j.jacc.2019.11.064>

© 2020 by the American College of Cardiology Foundation. Published by Elsevier.

Please note: Dr. Sugiyama has reported that he has no relationships relevant to the contents of this paper to disclose.

REFERENCES

1. Binding C, Bjerring Olesen J, Abrahamsen B, et al. Osteoporotic fractures in patients with atrial fibrillation treated with conventional versus direct anticoagulants. *J Am Coll Cardiol* 2019;74:2150-8.
2. Sugiyama T. Oral anticoagulation and hip fracture risk: a common misconception? *J Intern Med* 2018;284:321-2.
3. Sugiyama T, Kugimiya F, Kono S, Kim YT, Oda H. Warfarin use and fracture risk: an evidence-based mechanistic insight. *Osteoporos Int* 2015;26:1231-2.
4. Sugiyama T, Kono Y, Sekiguchi K, Kim YT, Oda H. An evidence-based perspective on warfarin and the growing skeleton. *Osteoporos Int* 2016;27:2883-4.
5. Gage BF. Warfarin-induced fractures in atrial fibrillation? *J Am Coll Cardiol* 2019;74:2159-61.

REPLY: Anticoagulant Therapy and Hip Fracture Risk



A Possible Involvement of Physical Activity

We thank Dr. Sugiyama for the letter regarding the results from our latest study “Osteoporotic Fractures in Patients With Atrial Fibrillation Treated With Conventional Versus Direct Anticoagulants.”

Our study did not find a statistically significant reduction in hip fractures among patients treated with direct oral anticoagulants (DOACs) compared with vitamin K antagonists (VKAs) (1). However, the analysis showed a trend supporting the main theory of the study, and our estimate of the relative risk of hip fractures was 0.91 among DOAC-treated patients compared with VKA-treated patients. The reason that the effects of VKA treatment were not significantly